Illumina and Oxford Uni to sequence complete rare disease genomes
This article was originally published in Scrip
The genomes of 500 people with a range of rare diseases are to be sequenced in full under a new collaboration between the University of Oxford (UK) and Illumina (US).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.